Intermittent MEK inhibition for the treatment of metastatic uveal melanoma

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma

IntroductionUveal melanoma (UM) is associated with poor outcomes in the metastatic setting and harbors activating mutations resulting in upregulation of MAPK signaling in almost all cases. The efficacy of selumetinib, an oral allosteric inhibitor of MEK1/2, was limited when administered at a continu...

Full description

Bibliographic Details
Main Authors: Shaheer Khan, Sapna P. Patel, Alexander N. Shoushtari, Grazia Ambrosini, Serge Cremers, Shing Lee, Lauren Franks, Shahnaz Singh-Kandah, Susana Hernandez, Naomi Sender, Kristina Vuolo, Alexandra Nesson, Prabhjot Mundi, Benjamin Izar, Gary K. Schwartz, Richard D. Carvajal
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
uveal melanoma
metastatic
MEK inhibition
intermittent dosing
selumetinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.975643/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.975643/full

Similar Items